Overview

Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death

Status:
Withdrawn

Trial end date:
2020-04-30

Target enrollment:

Participant gender:

Summary

This is a multi-center, randomized controlled, superiority, open label trial. The objective of this trial is to evaluate the efficacy of HCQ in patients with newly diagnosed COVID-19 who have mild to moderate disease or at risk for complications. We aim to demonstrate decrease in progression to severe pneumonia and hospital related complications among patients who are treated with HCQ compared to patients who are not.

Phase:

Early Phase 1

Details

Lead Sponsor:

Rambam Health Care Campus

Collaborator:

Rabin Medical Center

Treatments:

Hydroxychloroquine